MX2022015874A - Anticuerpos terapeuticos anti polipeptido activador de monocitos endoteliales ii (emap ii) humanizados. - Google Patents

Anticuerpos terapeuticos anti polipeptido activador de monocitos endoteliales ii (emap ii) humanizados.

Info

Publication number
MX2022015874A
MX2022015874A MX2022015874A MX2022015874A MX2022015874A MX 2022015874 A MX2022015874 A MX 2022015874A MX 2022015874 A MX2022015874 A MX 2022015874A MX 2022015874 A MX2022015874 A MX 2022015874A MX 2022015874 A MX2022015874 A MX 2022015874A
Authority
MX
Mexico
Prior art keywords
emap
humanized anti
therapeutic antibodies
bind
treatment
Prior art date
Application number
MX2022015874A
Other languages
English (en)
Inventor
Douglas W P Hay
Suzanne E Berezovsky
Kexin Huang
Jordon K Wang
David Knight
Original Assignee
Allinaire Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allinaire Therapeutics Llc filed Critical Allinaire Therapeutics Llc
Publication of MX2022015874A publication Critical patent/MX2022015874A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona anticuerpos monoclonales que se unen a un polipéptido activador de monocitos endoteliales II y métodos de tratamiento que usan los mismos.
MX2022015874A 2020-06-29 2021-06-28 Anticuerpos terapeuticos anti polipeptido activador de monocitos endoteliales ii (emap ii) humanizados. MX2022015874A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063045687P 2020-06-29 2020-06-29
PCT/US2021/039389 WO2022005979A1 (en) 2020-06-29 2021-06-28 Humanized anti-emap ii therapeutic antibodies

Publications (1)

Publication Number Publication Date
MX2022015874A true MX2022015874A (es) 2023-03-03

Family

ID=79314890

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015874A MX2022015874A (es) 2020-06-29 2021-06-28 Anticuerpos terapeuticos anti polipeptido activador de monocitos endoteliales ii (emap ii) humanizados.

Country Status (14)

Country Link
US (1) US20230287095A1 (es)
EP (1) EP4171634A1 (es)
JP (1) JP2023533514A (es)
KR (1) KR20230029774A (es)
CN (1) CN115996753A (es)
AU (1) AU2021299452A1 (es)
BR (1) BR112022025264A2 (es)
CA (1) CA3181077A1 (es)
CL (1) CL2022003771A1 (es)
CO (1) CO2023000343A2 (es)
IL (1) IL299548A (es)
MX (1) MX2022015874A (es)
PE (1) PE20230442A1 (es)
WO (1) WO2022005979A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012267530A1 (en) * 2011-06-08 2014-01-16 Indiana University Research And Technology Corporation Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
US10132815B2 (en) * 2013-02-13 2018-11-20 Indiana University Research & Technology Corporation Methods of diagnosing, treating and monitoring diabetic retinopathy
JP6343011B2 (ja) * 2013-10-07 2018-06-13 プレステージ バイオファーマ プライベート リミテッド 抗体発現用バイシストロニック発現ベクター及びそれを用いた抗体の生産方法
AU2019369498A1 (en) * 2018-10-31 2021-05-20 Delinia, Inc. Multivalent regulatory T cell modulators

Also Published As

Publication number Publication date
WO2022005979A1 (en) 2022-01-06
KR20230029774A (ko) 2023-03-03
JP2023533514A (ja) 2023-08-03
PE20230442A1 (es) 2023-03-08
AU2021299452A1 (en) 2023-02-02
US20230287095A1 (en) 2023-09-14
EP4171634A1 (en) 2023-05-03
CN115996753A (zh) 2023-04-21
CO2023000343A2 (es) 2023-04-17
BR112022025264A2 (pt) 2023-01-03
CL2022003771A1 (es) 2023-05-26
CA3181077A1 (en) 2022-01-06
IL299548A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
MX2020009121A (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de produccion de anticuerpos anti-sirpa v1.
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
MX2022001260A (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
ZA202008095B (en) Humanized antibodies against psma
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2022015874A (es) Anticuerpos terapeuticos anti polipeptido activador de monocitos endoteliales ii (emap ii) humanizados.
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
EA201992324A1 (ru) Анти-trem2 антитела и способы их применения
MX2023002984A (es) Nuevos anticuerpos anti-a2ap y usos de los mismos.
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA202092640A1 (ru) Способы и композиции для лечения хронической крапивницы
EA201992335A1 (ru) Антитела против сортилина и способы их применения